'Himalayan Viagra': the world's most coveted fungus
When you buy through links on our articles, Future and its syndication partners may earn a commission.
On the hit zombie TV show "The Last of Us", cordyceps fungus mostly turns people into "superstrong killing machines", said Bloomberg.
But in traditional medicine, the chilli-shaped fungi are "prized as a panacea" and "an aphrodisiac" – so much so that one species found throughout the Himalayas, cordyceps sinensis, is "worth four times its weight in gold". But the booming demand for this so-called "Himalayan Viagra" is taking its toll on a vulnerable region.
In the remote, high-altitude pastures of Tibet, Nepal, Bhutan and India, the cordyceps is known by the Tibetan phrase yartsa gunbu ("summer grass, winter worm"). It is believed to strengthen lungs and kidneys, as well as increase vitality. It's also prized in traditional Chinese medicine as an aphrodisiac.
And it's lately had "something of a modern coming-out party", said Bloomberg. In 1993, a Chinese track coach attributed "a series of record-breaking runs" to a tonic made from the fungus.
Since Nepal legalised trade in 2001, it has become a "coveted gift" in China, South Korea and Japan: "a way to show off". Cheap supplements promising "synthetic slivers of cordyceps" can be bought everywhere from Whole Foods to Amazon. In 2013, researchers estimated that the global market was worth as much as $11 billion (£8.7 billion) a year.
It is "the world's most highly prized parasite", said Oryx Journal, and one of the most important sources of income in the extremely poor region. But little is known about its trade, while its harvest and sale is "often illegal and unsustainable".
In 2020, the non-profit organisation International Union for Conservation of Nature listed yartsa as vulnerable to extinction, saying it had declined by at least 30% over 15 years.
Its price and scarcity means yartsa "hasn't been studied much in the West", said New Scientist. But researchers in China, Nepal and India have documented its potential benefits for liver, kidney and cardiovascular disease, as well as possible "anti-inflammatory and anti-viral effects". Scientists at the University of Oxford are also studying its potential as an anti-cancer drug.
The increasing demand for yartsa is having "a huge ecological impact" on the region, which is already "warming at double the global average rate". Digging for the fungus increases erosion and harvesting methods can pollute rivers and lead to deforestation.
It's also dangerous for the people gathering yartsa on treacherous terrain that's vulnerable to flash floods and avalanches, said Bloomberg. In 2023, more people died hunting yartsa than "summiting Mount Everest".
The yartsa trade also "relies significantly on child labour", and the potential pay-offs are fuelling smuggling and turf-war violence.
"People fight and die over it, and we're not even sure it works," said Rajendra Bajgain, a member of Nepal's House of Representatives. "Yartsa needs regulation, and we need to shore up our borders. What's really unbelievable is how many people come from China to buy it and smuggle it home. It's out of control."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
9 hours ago
- Epoch Times
Relieve Sciatica Pain With 1 Simple TCM Stretch
Deep within your body lies the sciatic nerve, a remarkable superhighway that stretches from your lower back, winds through your hips, and extends down to the soles of your feet. As one of the longest nerves in the human body, it's a powerhouse of sensation and movement. However, when this nerve becomes pinched or irritated, it unleashes sciatica—a fiery, radiating pain that can turn even the most mundane steps into a grueling challenge. Enter Hung-chien Wu, the director of Taiwan's Yi-Sheng Chinese Medicine Clinic, who once battled the relentless grip of sciatica himself. Through a single stretching exercise, he managed to tame his pain and reclaim his life. Now, armed with the wisdom of traditional Chinese medicine (TCM), Wu has guided tens of thousands of patients to freedom from sciatica, helping them rediscover the joy of pain-free living with his proven, holistic approach. Acupuncture and Chinese Medicine Are Effective Modern Western medical treatments for sciatica, such as spinal traction, can temporarily relieve nerve compression. However, without ongoing treatment and proper spinal posture, the spine may compress the nerve again under the influence of gravity.
Yahoo
12 hours ago
- Yahoo
New study reveals concerning hazard in water near closed factory: 'Cannot be ignored'
A group of researchers recently looked at potential PFAS contamination around an out-of-use manufacturing plant in China. The resulting study shows that the "forever chemicals" nickname given to PFAS is a fitting one. The water sources surrounding the defunct plant showed significant levels of these dangerous synthetic substances. PFAS, or per- and polyfluoroalkyl substances, are a group of thousands of synthetic chemicals used in everything from cosmetics to nonstick pans to medical devices. While they offer a remarkable range of applications, these chemicals are known to have a tremendous array of health risks. Among them are reproductive issues, liver damage, and cancer. Though the Chinese fluorochemical manufacturing plant this study focused on was no longer in operation, researchers suspected that toxic PFAS were still present. They tested for the presence of 17 PFAS in the surrounding river and ground and drinking water within a 13-kilometer radius of the facility. Eleven of the 17 were detected, including perfluorooctane sulfonate and perfluorooctanoic acid, two notably dangerous chemicals. Considering the serious health risks associated with PFAS, it's critical to understand where contamination exists. Children are particularly vulnerable to these chemicals, as they can cause developmental issues with lifelong consequences. Perhaps the most alarming aspect of PFAS is that they don't break down for years, and possibly even decades. That's why they're often referred to as forever chemicals. This study in particular is critical, as it shows that PFAS contamination can persist long after facilities that produce them are shut down. While many may have assumed that the Chinese facility no longer posed health risks to surrounding communities, this study clearly shows that's not the case. As the research team put it, "The potential threat of the closed fluorochemical manufacturing plant to the surrounding waters cannot be ignored." While PFAS have been around for many decades, it wasn't until recently that their health risks were taken seriously. Chemical manufacturers Chemours, DuPont, and Corteva recently agreed to a $1.2 billion settlement for contaminating American waters with PFAS. Meanwhile, the looming threat of more litigation has inspired German insurers to reduce PFAS-related commercial and product liability policies. If you want to avoid PFAS, reducing reliance on plastic food packaging is a great start. You can also avoid nonstick cookware and choose PFAS-free clothing, cosmetics, and furniture. How often do you worry about the quality of your drinking water? Never Sometimes Often Always Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Yahoo
14 hours ago
- Yahoo
There's a new blood test for Alzheimer's. Here's everything you need to know.
When you buy through links on our articles, Future and its syndication partners may earn a commission. The U.S. Food and Drug Administration (FDA) recently cleared a blood test that detects signs of Alzheimer's disease in the brain, according to multiple studies. This is the first-ever blood test available for this common form of dementia. Here's how the new blood test works and why it could be useful to patients. Alzheimer's disease is on the rise, in part because the age group most prone to dementia is growing larger. In the U.S., an estimated 7.2 million Americans ages 65 and older are living with Alzheimer's dementia in 2025. The percentage of affected people increases with age: About 5% of people ages 65 to 74 have Alzheimer's, compared with more than 33% of people ages 85 and older. At the point when a doctor has verified that a patient has cognitive decline, the blood test can be used in place of standard tests to see if they likely have Alzheimer's. Previously, gold-standard methods of diagnosing Alzheimer's have been more invasive and expensive, involving positron emission tomography (PET) scans, which use radioactive substances; and lumbar punctures, (also called spinal taps) during which a clinician uses a needle to sample spinal fluid from the low back. Clinicians also sometimes use MRIs or CT scans to rule out other causes of cognitive decline. The new test measures the ratio of two proteins in human blood, and this ratio correlates with the presence or absence of amyloid plaques, a primary sign of Alzheimer's found in the brain. For people experiencing memory lapses that might be due to Alzheimer's, the first step is to see their primary care physician (PCP), who should do a cognitive test. If there are signs of cognitive impairment, the patient would then be referred to a neurologist for an in-depth evaluation. Both dementia specialists and PCPs will be able to order this blood test to help with diagnosis, said Dr. Gregg Day, a neurologist with the Mayo Clinic in Jacksonville, Florida; Day led a study of the blood test published in June in the Journal of the Alzheimer's Association. A study published in 2024 in JAMA found that whether the test was ordered by a PCP or specialist, it was equally accurate at confirming suspected Alzheimer's diagnoses. PCPs could use the test results to decide whether to refer patients to a specialist, who could prescribe treatments such as lecanemab or donanemab, Day said. Or the PCP could personally prescribe a medicine like donepezil, which can help improve mental function in Alzheimer's. With FDA clearance, Medicare and private health insurance providers alike are expected to cover the new blood test, Day said. The test — called the "Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio" — is intended for people ages 55 and older who show signs and symptoms of cognitive decline that have been confirmed by a clinician. The test is designed for the early detection of amyloid plaques associated with Alzheimer's disease. (Amyloid plaques are unusual clumps found between brain cells and made up of a type of protein called beta-amyloid.) Related: Man nearly guaranteed to get early Alzheimer's is still disease-free in his 70s — how? Early detection is important, said Dr. Sayad Ausim Azizi, clinical chief of behavioral neurology and memory disorders at the Yale School of Medicine. That's because the Alzheimer's brain is like a rusty engine — the plaque is like rust settling onto the engine, interfering with the wheels' ability to turn, Azizi told Live Science. There are FDA-approved treatments that act like oil, helping the wheels to turn, but the medication does not remove the rust itself, he said. Available therapies can slow down the degradation of the brain by about 30% to 40%, studies show, so the patient can retain function for longer. "If you're driving now and living independently and you don't take the medicine, it's likely in five years you won't be able to do all these things," Azizi said, providing a hypothetical example. "If you take the medicine, the five years are extended to eight." If adopted as intended, the new blood test could help more people access these treatments sooner. The test is not recommended for the purposes of screening the general population. It is intended only for people who have been found by a doctor to exhibit signs of Alzheimer's disease, Day and Azizi emphasized. Some amount of amyloid is present in the brain during healthy aging, so its presence doesn't guarantee someone will later have Alzheimer's. If the test detects signs of amyloid plaques 20 years before any cognitive symptoms surface, Azizi explained, it would not make sense to treat the patient at that time. "The treatments are not 100% benign," he added. To receive lecanemab, for example, patients must be able to receive an infusion every two weeks at first and every four weeks later on; donanemab is given every four weeks. Both medications can come with infusion-related reactions, such as headache, nausea and vomiting. Rarely, the treatment donanemab can cause life-threatening allergic reactions, and both lecanemab and donanemab have been tied to rare cases of brain swelling or bleeding in the brain. These latter side effects are related to "amyloid-related imaging abnormalities," which are structural abnormalities that appear on brain scans. The new test can give false positives, meaning a person can potentially test positive when they don't actually have Alzheimer's. That's because the signs of amyloid that the tests look for can be tied to other conditions. For instance, amyloid buildup in the brain could be a sign the kidneys are not functioning optimally, Day said, so he recommends also doing a blood test for kidney function when ordering the Alzheimer's blood test. The Mayo Clinic study included about 510 people, 246 of whom showed cognitive decline; the blood test confirmed 95% of those with cognitive symptoms had Alzheimer's. About 5.3% of cases showed a false negative on the blood test, while 17.6% of cases gave a false positive, Day said. Most of the false-positive patients still had Alzheimer's-like changes in their brains, but their symptoms were ultimately attributed to other diseases, such as Lewy body dementia, Day said. The Mayo study found that the blood test helped doctors distinguish Alzheimer's from these other forms of dementia. As is true of many clinical trials, evaluations of the test have primarily included populations that are healthier than average, Day said. These individuals are not only healthier at baseline, but are more likely to have health insurance and be white and non-Hispanic. So when the blood test is used in a broader population, there may be people with sleep apnea or kidney disease who test positive despite not having Alzheimer's, Day said. Some people with these health problems may also experience memory issues or cognitive impairment that's not caused by Alzheimer's disease. If the blood test points to amyloid buildup, doctors could order additional tests and ask patients about their sleep to help rule out these other possibilities. RELATED STORIES —Could vaccines prevent and treat Alzheimer's disease? —Study unravels whole new layer of Alzheimer's disease —Alzheimer's comes in at least 5 distinct forms, study reveals The test will give researchers a more precise idea of how a patient's clinical symptoms relate to the findings on their blood test, Azizi said. "It's a great way of using a biomarker [measurable sign of disease] in the blood to make an earlier diagnosis to give a drug" to slow disease progression, he said. Azizi added that this blood test could help track whether a treatment for Alzheimer's disease is working, which would be useful both for patients receiving approved medicines and those in trials of new drugs. Looking forward, researchers will also be able to evaluate how well blood-based testing works in more diverse populations, Day noted. This article is for informational purposes only and is not meant to offer medical advice.
